Alfredo Romano

1.3k total citations · 1 hit paper
19 papers, 1.0k citations indexed

About

Alfredo Romano is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alfredo Romano has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alfredo Romano's work include Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (12 papers) and Colorectal Cancer Treatments and Studies (6 papers). Alfredo Romano is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (12 papers) and Colorectal Cancer Treatments and Studies (6 papers). Alfredo Romano collaborates with scholars based in Spain, United States and Switzerland. Alfredo Romano's co-authors include Daniel D. Von Hoff, Josep Tabernero, David Goldstein, Werner Scheithauer, Darryl Penenberg, Robert H. El-Maraghi, Brian Lu, Volker Kunzmann, Salvatore Siena and Pascal Hammel and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Alfredo Romano

18 papers receiving 993 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 504 citations David Goldstein, Robert H. El-Maraghi et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfredo Romano Spain	12	842	346	280	219	189	19	1.0k
Tina E. Wood United States	7	900 1.1×	331 1.0×	218 0.8×	188 0.9×	173 0.9×	12	1.1k
Nikolaos Ziras Greece	17	996 1.2×	304 0.9×	369 1.3×	116 0.5×	207 1.1×	55	1.2k
Kim C. Honselmann Germany	16	807 1.0×	240 0.7×	311 1.1×	177 0.8×	352 1.9×	56	1.0k
B. Mirtsching United States	12	1.1k 1.4×	288 0.8×	459 1.6×	136 0.6×	131 0.7×	27	1.3k
Shannon McDonough United States	15	989 1.2×	302 0.9×	262 0.9×	206 0.9×	180 1.0×	35	1.2k
Aris Polyzos Greece	19	1.2k 1.4×	262 0.8×	607 2.2×	178 0.8×	267 1.4×	55	1.5k
Carlo Milandri Italy	15	677 0.8×	273 0.8×	261 0.9×	211 1.0×	114 0.6×	53	936
Henry Xiong United States	11	769 0.9×	221 0.6×	303 1.1×	228 1.0×	239 1.3×	20	1.1k
D. Quietzsch Germany	14	886 1.1×	291 0.8×	461 1.6×	191 0.9×	210 1.1×	30	1.1k
Jeroen Dekervel Belgium	18	617 0.7×	230 0.7×	165 0.6×	239 1.1×	110 0.6×	69	1.1k

Countries citing papers authored by Alfredo Romano

Since Specialization

Citations

This map shows the geographic impact of Alfredo Romano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfredo Romano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfredo Romano more than expected).

Fields of papers citing papers by Alfredo Romano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfredo Romano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfredo Romano. The network helps show where Alfredo Romano may publish in the future.

Co-authorship network of co-authors of Alfredo Romano

This figure shows the co-authorship network connecting the top 25 collaborators of Alfredo Romano. A scholar is included among the top collaborators of Alfredo Romano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfredo Romano. Alfredo Romano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Young, Rosemary, Paul N. Mainwaring, Philip Clingan, et al.. (2018). nab‐Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia-Pacific Journal of Clinical Oncology. 14(5). e325–e331. 4 indexed citations

Scheithauer, Werner, Ramesh K. Ramanathan, Malcolm J. Moore, et al.. (2016). Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Journal of Gastrointestinal Oncology. 7(3). 469–478. 47 indexed citations

Vogel, Arndt, et al.. (2016). Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer. 16(1). 817–817. 24 indexed citations

Ducreux, Michel, Jaafar Bennouna, Antoine Adenis, et al.. (2016). Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemotherapy and Pharmacology. 79(1). 9–16. 16 indexed citations

Tehfé, Mustapha, Scot Dowden, Hagen F. Kennecke, et al.. (2016). nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Advances in Therapy. 33(5). 747–759. 16 indexed citations

Chiorean, E. Gabriela, Daniel D. Von Hoff, Josep Tabernero, et al.. (2016). Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. British Journal of Cancer. 115(2). 188–194. 63 indexed citations

Riess, Hanno, Volker Kunzmann, Philip Agop Philip, et al.. (2016). A phase I safety and pharmacokinetic (PK) study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients (pts) with advanced pancreatic cancer (APC) who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction.. Journal of Clinical Oncology. 34(4_suppl). TPS474–TPS474.

Goldstein, David, E. Gabriela Chiorean, Josep Tabernero, et al.. (2016). Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 34(4_suppl). 333–333. 2 indexed citations

Hidalgo, Manuel, Carlos Plaza, Mónica Musteanu, et al.. (2015). SPARC Expression Did Not Predict Efficacy of nab -Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clinical Cancer Research. 21(21). 4811–4818. 102 indexed citations

10.

Goldstein, David, Robert H. El-Maraghi, Pascal Hammel, et al.. (2015). nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. JNCI Journal of the National Cancer Institute. 107(2). dju413–dju413. 504 indexed citations breakdown →

11.

Tabernero, Josep, E. Gabriela Chiorean, Jeffrey R. Infante, et al.. (2015). Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. The Oncologist. 20(2). 143–150. 110 indexed citations

12.

Goldstein, David, Robert H. El-Maraghi, Pascal Hammel, et al.. (2014). Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. Journal of Clinical Oncology. 32(15_suppl). 4027–4027. 11 indexed citations

13.

Goldstein, David, Pascal Hammel, Volker Heinemann, et al.. (2014). Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology. 32(3_suppl). 178–178. 27 indexed citations

14.

Siena, Salvatore, Eric Van Cutsem, Mingyu Li, et al.. (2013). Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer. PLoS ONE. 8(11). e62264–e62264. 18 indexed citations

15.

Gandhi, Anita K., Tao Shi, Mingyu Li, et al.. (2013). Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients. PLoS ONE. 8(11). e80437–e80437. 28 indexed citations

16.

Tabernero, Josep, Daniel D. Von Hoff, Malcolm Moore, et al.. (2013). Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors on Survival. Annals of Oncology. 24. iv11–iv12. 2 indexed citations

17.

Moore, Malcolm J., Daniel D. Von Hoff, Thomas J. Ervin, et al.. (2013). Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 31(15_suppl). 4059–4059. 3 indexed citations

18.

Giordano, Arturo & Alfredo Romano. (2011). Inhibition of human in-stent restenosis: a molecular view. Current Opinion in Pharmacology. 11(4). 372–377. 23 indexed citations

19.

Romano, Alfredo, et al.. (2010). Toward the optimization of stent-based treatment for coronary artery disease.. PubMed. 13(2). 157–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact